San Francisco-based UCSF Health and GE HealthCare have launched an innovation hub to propel medical imaging into the future.
Category: ROOT
False Claim Act recoveries hit $2.9B in 2024
Whisteblowers filed a record 979 qui tam lawsuits in 2024, according to a Jan. 15 Justice Department report.
Virginia hospital indicted for $18.5M fraud scheme, unnecessary surgeries
Chesapeake (Va.) Regional Medical Center, formerly known as Chesapeake Regional Hospital, has been indicted for healthcare fraud and conspiracy, accused of allowing Javaid Perwaiz, MD, to perform unnecessary procedures and submitting fraudulent claims …
Lee Health names COO
Ben Spence, a nearly 30-year veteran of Fort Myers, Fla.-based Lee Health, has been appointed COO.
Top 10 EHR implementation challenges
Implementations remain one of the weakest aspects of the EHR experience, with customer satisfaction dropping significantly since 2022, KLAS Research reported.
'Definitions matter': Cleveland Clinic's approach to hospital at home
Cleveland Clinic has grown its hospital-at-home program by “demonstrating value to patients and gaining adoption from brick-and-mortar caregivers,” a leader told Becker’s.
How Terry Shaw's 40-year journey positioned AdventHealth for the future
Terry Shaw’s four-decade career at AdventHealth played a significant role in guiding the organization’s strategic direction, uniting the health system under one brand and introducing the 10-year Vision 2030 plan. As he prepares to retire in July, …
Christus Health breaks ground on $36M cancer center
Irving, Texas-based Christus Health has broken ground on a $36 million cancer center in Longview, Texas.
Trump's plans for HHS: 13 knowns
President-elect Donald Trump’s HHS appointees represent a broad spectrum of healthcare perspectives and are poised to significantly influence public health, pharmaceuticals and health systems.
With a $1.8 trillion budget in 2024, the department’…
Watchdog flags flaws in FDA's fast-track drug approvals
A new report from HHS’ Office of Inspector General raises concerns about the FDA’s accelerated approval process for drugs with weak supporting evidence, Bloomberg reported Jan. 14.
